Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) EBITDA (2020 - 2023)

Terns Pharmaceuticals' EBITDA history spans 4 years, with the latest figure at -$21.0 million for Q4 2023.

  • For Q4 2023, EBITDA fell 24.61% year-over-year to -$21.0 million; the TTM value through Dec 2023 reached -$90.2 million, down 44.6%, while the annual FY2025 figure was -$110.1 million, 8.1% down from the prior year.
  • EBITDA reached -$21.0 million in Q4 2023 per TERN's latest filing, up from -$29.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$8.8 million in Q4 2020 to a low of -$29.8 million in Q3 2023.
  • Average EBITDA over 4 years is -$15.1 million, with a median of -$14.1 million recorded in 2021.
  • Peak YoY movement for EBITDA: decreased 5.28% in 2021, then plummeted 76.22% in 2023.
  • A 4-year view of EBITDA shows it stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022, then dropped by 24.61% to -$21.0 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's EBITDA are -$21.0 million (Q4 2023), -$29.8 million (Q3 2023), and -$18.3 million (Q2 2023).